Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine.

Por Pollard, S R, Dunn, G, Cammack, N, Minor, P D, Almond, J W
Publicado em 1989

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) e...

Por Gao, Q, Gu, Z, Parniak, M A, Cameron, J, Cammack, N, Boucher, C, Wainberg, M A
Publicado em 1993

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 rever...

Por Boucher, C A, Cammack, N, Schipper, P, Schuurman, R, Rouse, P, Wainberg, M A, Cameron, J M
Publicado em 1993

The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro.

Por Coates, J A, Cammack, N, Jenkinson, H J, Mutton, I M, Pearson, B A, Storer, R, Cameron, J M, Penn, C R
Publicado em 1992

Impact of Human Immunodeficiency Virus Type 1 gp41 Amino Acid Substitutions Selected during Enfuvirtide Treatment on gp41 Binding and Antiviral Potency of Enfuvirtide In Vitro

Por Mink, M., Mosier, S. M., Janumpalli, S., Davison, D., Jin, L., Melby, T., Sista, P., Erickson, J., Lambert, D., Stanfield-Oakley, S. A., Salgo, M., Cammack, N., Matthews, T., Greenberg, M. L.
Publicado em 2005

(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.

Por Coates, J A, Cammack, N, Jenkinson, H J, Jowett, A J, Jowett, M I, Pearson, B A, Penn, C R, Rouse, P L, Viner, K C, Cameron, J M
Publicado em 1992